To successfully develop an antibody-based therapy for T-ALL, several clones of anti-CD99 mAbs must be investigated for the anti-cancer effects in both direct killing effect and enhancing host immune effectors in vitro and in vivo. The gene discussed is CD99; the disease is cancer.